Caplin Point Lab Peer Comparison

NSE: CAPLIPOINT | BSE: 524742

₹2,517.20

₹-23.50 (-0.92%)

As on 28-Aug-2026IST

Market cap

₹19,125 Cr

Revenue (TTM)

₹2,287 Cr

P/E Ratio

28.7

P/B Ratio

5.1

Div. Yield

0.2 %

Edit

	Caplin Point Lab	Pfizer	Eris Lifesciences	Astrazeneca Pharma	Shilpa Medicare
Market cap (₹ Cr)	19,125	21,501	18,253	17,766	17,685
Revenue (₹ Cr)	2,287	2,570	3,230	2,432	1,682
Net Profit (₹ Cr)	678.07	735.15	666.92	169.62	273.51
Net Margin (%)	28.10	26.88	20.60	6.90	16.19
RoE (%)	19.73	19.16	18.75	20.76	11.15
Price to Earnings	28.74	29.25	28.35	104.74	59.48
Price-To-Book	5.08	4.88	4.51	19.65	6.58

Income Statement (₹ Cr)

	Caplin Point Lab	Pfizer	Eris Lifesciences	Astrazeneca Pharma	Shilpa Medicare
Operating Revenue	2,287.33	2,569.77	3,229.67	2,432.06	1,682.47
Total Income	2,413.29	2,735.39	3,237.12	2,458.54	1,689.83
Total Expenditure	1,490.75	1,628.14	2,090.06	2,202.20	1,203.91
EBITDA	796.58	941.63	1,139.61	229.86	478.55
Depreciation	78.10	57.58	281.06	17.24	126.01
EBIT	718.48	884.05	858.55	212.62	352.55
Interest	0.88	7.69	190.64	5.72	52.11
Other Income	125.96	165.62	7.45	26.48	7.37
Exceptional Items	0.00	-49.16	-17.24	-5.13	12.16
Profit before Tax	843.56	992.82	658.12	228.25	319.96
Provision for Tax	165.49	257.67	-8.80	58.63	46.45
Profit after Tax	678.07	735.15	666.92	169.62	273.51

	Caplin Point Lab	Pfizer	Eris Lifesciences	Astrazeneca Pharma	Shilpa Medicare
Shareholder's Funds	3,586.42	4,202.90	3,902.67	872.79	2,591.20
Minority Interest	-12.71	0.00	-21.81	0.00	0.00
Non-Current Liabilities	28.74	91.50	1,392.75	134.50	266.35
Current Liabilities	385.94	627.48	2,077.10	981.81	848.06
Total Liabilities	3,207.85	4,911.11	6,862.28	1,879.19	3,310.68

	Caplin Point Lab	Pfizer	Eris Lifesciences	Astrazeneca Pharma	Shilpa Medicare
Non-Current Assets	1,291.22	770.28	5,617.77	42.47	2,525.44
Current Assets	2,585.66	3,803.22	1,539.85	1,739.93	1,109.77
Total Assets	3,207.85	4,911.11	6,862.28	1,879.19	3,310.68
Total Debt*	0.55	2.50	2,421.66	0.00	586.37
Net Current Assets	2,199.72	3,175.74	-537.25	758.12	261.71
Contingent Liabilities	0.64	363.79	64.29	98.41	76.22

	Caplin Point Lab	Pfizer	Eris Lifesciences	Astrazeneca Pharma	Shilpa Medicare
Cash From Operating Activities	432.37	659.75	1,065.01	65.36	132.27
Cash Flow from Investing Activities	-334.73	-71.34	-79.97	30.80	-199.13
Cash from Financing Activities	-38.32	-205.34	-881.32	-65.59	62.65
Net Cash Inflow / Outflow	59.32	383.07	103.72	30.57	-4.21

	Caplin Point Lab	Pfizer	Eris Lifesciences	Astrazeneca Pharma	Shilpa Medicare
ROCE (%)	26.22	26.21	13.59	21.29	6.95
ROE (%)	19.73	19.16	18.75	20.76	11.15
ROA (%)	18.69	14.95	9.26	9.67	7.80
EBIT Margin (%)	31.41	34.40	26.58	8.74	20.95
Net Margin (%)	28.10	26.88	20.60	6.90	16.19
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Caplin Point Lab	Pfizer	Eris Lifesciences	Astrazeneca Pharma	Shilpa Medicare
Revenue Growth (%)	15.01	10.69	9.59	31.10	27.91
EBIT Growth (%)	18.45	24.14	16.84	-12.99	58.32
Net Profit Growth (%)	19.61	-9.09	62.68	-7.49	149.56
EPS Growth (%)	17.73	14.40	67.41	-18.33	-3.57
Book Value Growth (%)	23.77	17.30	10.19	7.70	30.63

	Caplin Point Lab	Pfizer	Eris Lifesciences	Astrazeneca Pharma	Shilpa Medicare
Price / Earnings	28.74	27.87	27.66	102.37	63.10
Price / Book Value	5.08	4.88	4.51	19.65	6.58
Dividend Yield (%)	0.16	1.60	0.55	0.51	0.07
EV/EBITDA	22.88	19.53	17.94	75.34	38.24
Market Cap (₹ Cr)	15,219.80	18,318.10	19,292.77	21,515.93	6,484.12

	Caplin Point Lab	Pfizer	Eris Lifesciences	Astrazeneca Pharma	Shilpa Medicare
Debt to Equity	0.00	0.00	0.24	0.00	0.07
Short term debt to equity ratio	0.00	0.00	0.14	--	0.13
Current Ratio	6.70	6.06	0.74	1.77	1.31
Quick Ratio	5.59	5.31	0.53	0.73	0.88
Interest Coverage	959.59	130.11	4.45	40.90	7.14

	Caplin Point Lab	Pfizer	Eris Lifesciences	Astrazeneca Pharma	Shilpa Medicare
Debtors to sales (%)	36.10	7.07	21.07	8.79	30.84
Asset Turnover	0.63	0.52	0.45	1.39	0.48
Receivable days	110.70	29.10	54.07	35.81	118.15
Inventory Days	65.86	69.53	32.16	82.25	98.29
Payable days	105.88	76.77	140.91	124.39	128.16
Cash Conversion Cycle	70.68	21.86	-54.68	-6.33	88.28

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.